Products
Tildrakizumab was approved as an injectable in the United States and EU in 2018 and in many countries in 2019 (ilumetri).
Structure and properties
Tildrakizumab is a humanized IgG1/k monoclonal antibody with an approximate molecular mass of 147 kDa. It is produced by biotechnological methods.
Effects
Tildrakizumab (ATC L04AC17) has immunosuppressive and anti-inflammatory properties. The effects are due to binding to the p19 subunit of interleukin-23 (IL-23). This prevents interaction with the receptor. IL-23 is a natural cytokine involved in the inflammatory response and plays a role in the immune response. Tildrakizumab inhibits the release of cytokines and chemokines. The half-life is approximately 23 days.
Indications
For the treatment of adult patients with moderate-to-severe plaque psoriasis who have had an inadequate response to prior conventional systemic therapy and/or PUVA or who have a contraindication or intolerance to such therapies.
Dosage
According to the SmPC. The drug is injected as a subcutaneous injection.
Contraindications
- Hypersensitivity
- Clinically relevant active infections, e.g., active tuberculosis.
Full precautions can be found in the drug label.
Interactions
Tildrakizumab should not be combined with live vaccines.
Adverse effects
The most common possible adverse effects include upper respiratory tract infections, headache, gastroenteritis, nausea, diarrhea, injection site pain, and back pain. Tildrakizumab increases the risk for infectious diseases.
